Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- RDUS
- Price
- 29.07
- Stock movement up
- +0.08 (0.28%)
- Company name
- Radius Heal
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.38B
- Ent value
- 1.74B
- Price/Sales
- 6.20
- Price/Book
- -
- Div yield
- 2.61%
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 111.81
- PEG
- -
- EPS growth
- -18.96%
- 1 year return
- 54.22%
- 3 year return
- 47.98%
- 5 year return
- 18.91%
- 10 year return
- -3.20%
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
RDUS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6.20 |
| Price to Book | - |
| EV to Sales | 7.79 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 47.62M |
| EPS (TTM) | -1.44 |
| FCF per share (TTM) | -0.59 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 223.36M |
| Gross profit (TTM) | 203.09M |
| Operating income (TTM) | -50.72M |
| Net income (TTM) | -68.63M |
| EPS (TTM) | -1.44 |
| EPS (1y forward) | 0.26 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 90.93% |
| Operating margin (TTM) | -22.71% |
| Profit margin (TTM) | -30.72% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 72.49M |
| Net receivables | 32.01M |
| Total current assets | 146.41M |
| Goodwill | 0.00 |
| Intangible assets | 4.59M |
| Property, plant and equipment | 0.00 |
| Total assets | 154.44M |
| Accounts payable | 14.48M |
| Short/Current long term debt | 340.40M |
| Total current liabilities | 87.86M |
| Total liabilities | 427.84M |
| Shareholder's equity | -273.40M |
| Net tangible assets | -277.99M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -27.50M |
| Capital expenditures (TTM) | 405.00K |
| Free cash flow (TTM) | -27.91M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -44.44% |
| Return on Invested Capital | -103.06% |
| Cash Return on Invested Capital | -41.91% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 29.08 |
| Daily high | 29.10 |
| Daily low | 28.81 |
| Daily Volume | 868K |
| All-time high | 80.63 |
| 1y analyst estimate | 9.60 |
| Beta | 0.52 |
| EPS (TTM) | -1.44 |
| Dividend per share | 0.76 |
| Ex-div date | 21 Apr 2025 |
| Next earnings date | 30 Jun 2025 |
Downside potential
Loading...
Downside potential data
| RDUS | S&P500 | |
| Current price drop from All-time high | -63.95% | -12.89% |
| Highest price drop | -93.14% | -56.47% |
| Date of highest drop | 11 May 2022 | 9 Mar 2009 |
| Avg drop from high | -60.90% | -11.07% |
| Avg time to new high | 56 days | 12 days |
| Max time to new high | 2450 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.38B
Marketcap category
Small-cap
Description
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.
Employees
293
Website
Investor relations
-
SEC filings
CEO
Jesper Høiland
Country
USA
City
Waltham
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page